How does IGC's Q3 2025 forecast compare to past performance?

IGC's Q3 2025 forecast shows a significant decline in estimated EPS and revenue compared to the past performance in Q3 2024. 1. **Comparison of Estimated EPS**: - In Q3 2025, the estimated EPS is -$0.02. - In Q3 2024, there was no reported EPS data. However, the net loss for Q3 2024 was $5.59 million or $0.09 per share. - The decline in estimated EPS indicates a potential worsening financial performance in Q3 2025 compared to the previous year. 2. **Comparison of Estimated Revenue**: - The estimated revenue for Q3 2025 is $300,000. - In Q3 2024, the revenue was $204,000. - This increase in estimated revenue from Q3 2024 to Q3 2025 suggests a potential improvement in sales performance, which is a positive indicator. 3. **Overall Performance Analysis**: - IGC Pharma has seen a strategic shift and significant intellectual property milestones, including groundbreaking patents in Europe and Mexico. - Despite a decline in quarterly revenue, the company has shown optimism about its potential blockbuster drug IGC-AD1 for Alzheimer's treatment. - The increase in revenue from $204,000 in Q3 2024 to $257,000 in Q3 2025 indicates a positive trend in sales performance. In conclusion, while IGC Pharma has shown potential with its strategic moves and the promising potential of its drug pipeline, the estimated EPS decline in Q3 2025 compared to the previous year's net loss suggests that the company is facing significant challenges. However, the increase in estimated revenue from Q3 2024 to Q3 2025 is a positive sign, indicating that the company's strategic shifts and new patents could be contributing to improved sales performance.